Manufacture

UC Davis joins Orgenesis’ point-of-care network to develop and commercialize cell and gene therapies in house.

What challenges do manufacturers face in developing ADCs?

John Rossi, Director of Translational Sciences at Kite Pharma, talks about bright future of CAR T cell therapy.

Dick Sundh, Head of Europe at Kite, explains what it takes to commercialize CAR T cell therapy.

Ravi Nalliah explains his journey from biochemistry and molecular biology student, to chartered accountant, to supply chain CDMO founder.

Here we explore the challenges involved in ensuring CAR T cell therapies are delivered to patients safely and as quickly as possible.

It is time to rethink traditional approaches to biosafety.

It's time to vote for the grand winner of The Medicine Maker Innovation Awards.

If we learn more about drug–nutrient interactions, we may be on the path towards better medicines.

How can pharmaceutical packaging be adapted to meet patient and supply chain requirements?